Poor solubility is an increasingley common problem in Drug Development and Discovery, it impacts on a technology in two main ways. A soluble formulation is required early on for early animal proof of concept studies which adds to the project risk if large amounts of money are going to be spent before you know if you have a good product opportunity. Secondly it will add to your cost of materials once your product is finally developed.
The first of these risks however can be manged, one of Damien’s clients, Agenda1, has developed a service that can help. SOLENT (SOLubility ENhancement Technology), the foundation is a proprietary pre-formulation matrix, comprising a wide variety of combinations of liquid-based GRAS (generally regarded as safe) formulation excipients approved for preclinical and clinical use (including pH adjustment, co-solvents, mico-emulations, SEDDS, oils, lipids and cyclodextrins).
The technology enables products to be “screened” in various potential formulations to quickly ascertain potential formulations, its quick and cheep enough to get your product into animals and man for Proof of concept and early safety studies. Then with a positive result you can confidently invest in a full formulation programme.
For more information on this vital new service contact: Ian Siragher at Agenda1 on 01274 326073
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology), we work with our clients to define a development target, define a development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch using the contact form or email Damien at damien.bove@idaconsultants.com
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
